Syncom Formulations (India) Ltd Falls to 52-Week Low of Rs.14

Stock Price Movement and Market Context

On 6 January 2026, Syncom Formulations (India) Ltd’s share price fell to Rs.14, the lowest level recorded in the past year. This represents a notable drop from its 52-week high of Rs.23.46, reflecting a decline of approximately 40.3% from that peak. The stock has underperformed its sector and the broader market, with a day change of -0.85% and a two-day consecutive fall resulting in a cumulative loss of -3.11%. Furthermore, the stock has underperformed the Pharmaceuticals & Biotechnology sector by -1.73% on the day.

In contrast, the Sensex opened lower by 108.48 points and was trading at 85,137.20, down 0.35%. Despite this, the Sensex remains close to its 52-week high of 86,159.02, just 1.2% away, and is trading above its 50-day moving average, signalling a generally bullish trend in the broader market. Syncom Formulations, however, is trading below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – indicating sustained downward momentum in its share price.

Long-Term Performance and Financial Metrics

Over the last year, Syncom Formulations has delivered a negative return of -28.40%, significantly lagging behind the Sensex’s positive 9.20% return. The stock’s performance also trails the BSE500 index, which generated 7.79% returns over the same period. This underperformance is reflective of the company’s subdued growth trajectory and market sentiment.

Financially, the company has experienced a decline in net sales and operating profit over the past five years, with net sales shrinking at an annual rate of -63.63% and operating profit decreasing by -52.27%. These figures highlight challenges in sustaining long-term growth within its industry segment.

Shareholding and Market Perception

Domestic mutual funds hold no stake in Syncom Formulations, which is notable given their capacity for detailed company research. This absence of institutional investment may reflect a cautious stance towards the company’s valuation or business prospects at current price levels. The company’s Mojo Score stands at 46.0, with a Mojo Grade of Sell, downgraded from Hold as of 1 August 2025, signalling a less favourable outlook from a quantitative perspective.

Recent Financial Highlights and Profitability

Despite the stock’s price decline, Syncom Formulations has reported positive financial results in recent quarters. The company has declared positive results for six consecutive quarters, with operating profit growing by 8.29% in the latest period. The latest half-year figures show a net sales growth of 25.87% to Rs.238.62 crores and a profit after tax (PAT) increase of 72.46% to Rs.32.32 crores. Return on capital employed (ROCE) for the half-year stands at a robust 22.06%, while return on equity (ROE) is at 16.6%, indicating efficient utilisation of capital.

Syncom’s debt-to-equity ratio remains low at an average of 0.05 times, reflecting a conservative capital structure with limited leverage. The stock trades at a price-to-book value of 3.5, which is a premium relative to its peers’ historical valuations. The company’s PEG ratio is 0.2, suggesting that earnings growth is not fully reflected in the current share price.

Valuation and Market Grade

Syncom Formulations’ market capitalisation grade is rated at 3, reflecting its mid-tier size within the Pharmaceuticals & Biotechnology sector. The downgrade from Hold to Sell in its Mojo Grade underscores concerns about the company’s growth prospects and relative valuation. The stock’s current trading below all major moving averages further emphasises the prevailing downward trend in price momentum.

While the company has demonstrated profit growth of 90.1% over the past year, this has not translated into positive returns for shareholders, as the stock price has declined by 28.50%. This divergence between earnings growth and share price performance highlights the market’s cautious stance on the company’s outlook.

Summary of Key Metrics

To summarise, Syncom Formulations (India) Ltd’s stock has reached a 52-week low of Rs.14, reflecting a challenging period marked by underperformance relative to the broader market and sector indices. The company’s financial results show pockets of strength in profitability and capital efficiency, but these have yet to be mirrored in the stock’s market valuation. The absence of domestic mutual fund holdings and the downgrade in Mojo Grade to Sell further illustrate the tempered market sentiment.

Investors and market participants will note the contrast between the company’s recent positive earnings trajectory and the persistent weakness in its share price, which remains below all key moving averages. This dynamic underscores the complexity of the stock’s current position within the Pharmaceuticals & Biotechnology sector.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today